Allergen-Encapsulating Nanoparticles Reprogram Pathogenic Allergen-Specific Th2 Cells to Suppress Food Allergy.

Area of Science:

• Immunology
• Nanotechnology
• Allergy Research

Background:

• Food allergy is a widespread and potentially fatal condition driven by pathogenic Th2 cells.
• Current allergen-specific immunotherapies (AIT) often require long treatment durations and provide only temporary symptom relief.
• Existing AIT may be limited by insufficient targeting of the underlying Th2 immune responses.

Purpose of the Study:

• To investigate the efficacy of allergen-encapsulating nanoparticles (NPs) in directly suppressing pathogenic Th2 responses in a mouse model of food allergy.
• To elucidate the mechanisms by which NP-based therapy modulates immune responses in food allergy.

Main Methods:

• Utilized poly(lactide-co-glycolide) nanoparticles (NPs) encapsulating allergens.
• Administered two intravenous doses of allergen-loaded NPs in a mouse model.
• Assessed anaphylaxis following oral food challenge (OFC).
• Analyzed changes in T cell populations (regulatory T cells, anergic T cells) and mast cell degranulation.

Main Results:

• NP treatment significantly reduced anaphylaxis severity after OFC.
• NPs promoted the accumulation of antigen-specific regulatory T cells in the gut.
• Therapy reprogrammed pathogenic Th2 cells into regulatory and anergic phenotypes.
• Reduced effector cell frequency and mast cell degranulation were observed.

Conclusions:

• Allergen-encapsulating NPs offer a rapid and effective strategy for attenuating allergic responses.
• This NP-based immunotherapy targets and modifies pathogenic Th2 cells, providing a potential new therapeutic avenue.
• The findings advance understanding of immunotherapy mechanisms for allergic diseases.